MPS is a group of rare, progressive genetic disorders and we’re working hard to advance new potential #GeneTherapies for MPS I and MPS II in partnership with @REGENXBIO!
Learn more about #MPS here: https://impsn.ca/mpsday/
Another big step forward for the #MPSII community!
We’re delighted to share that the FDA has accepted the Biologics License Application for RGX-121, a potential first-in-class, one-time #GeneTherapy developed by our partners at @REGENXBIO!
Don't miss Dr. Aoki's presentation tomorrow at 5:30pm in Poster Hall I2. They'll be sharing results from the NS-089 clinical trial, offering new insights into potential therapies for #Duchenne muscular dystrophy.